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Traditional studies of neuroanatomical connections
require injection of tracer compounds into living
brains, then histology of the postmortem tissue.
Here, we describe and validate a compound that
reveals neuronal connections in vivo, using MRI.
The classic anatomical tracer CTB (cholera-toxin
subunit-B)was conjugatedwith agadolinium-chelate
to form GdDOTA-CTB. GdDOTA-CTB was injected
into the primary somatosensory cortex (S1) or the
olfactory pathwayof rats. High-resolutionMR images
were collected at a range of time points at 11.7T
and 7T. The transported GdDOTA-CTB was visible
for at least 1 month post-injection, clearing within
2 months. Control injections of non-conjugated
GdDOTA into S1 were not transported and cleared
within 1–2 days. Control injections of Gd-Albumin
were not transported either, clearing within 7 days.
TheseMR resultswere verifiedbyclassic immunohis-
tochemical staining for CTB, in the same animals.
The GdDOTA-CTB neuronal transport was target
specific, monosynaptic, stable for several weeks,
and reproducible.
INTRODUCTION
Defining the anatomical connections of the brain is crucial for
understanding its functions. In addition to revealing normal
circuitry, studies of anatomical connections can show rewiring
and outgrowth during development or degeneration following
brain injury.
To reveal anatomical circuits, conventional approaches
require injection of tracers in vivo, followed by sacrifice after a
specific and limited survival time, and followed by histological
processing of the ex vivo tissue. This approach requires a large
sample size in order to compare the results across animals, and
it is not suitable for chronic or longitudinal experiments.Recent developments in MR neuroimaging have begun to
reveal information on brain connections in vivo. Diffusion tensor
imaging (DTI) has been widely used to study major white matter
bundles (‘‘tractography’’) in humans (Le Bihan et al., 2001).
However, even when based on sophisticated data acquisition
and mathematical calculations, DTI estimates large fiber tracts
rather than revealing connections per se. Therefore, it cannot
reveal whether or not one brain region is connected with another,
nor can it determine whether the fiber tract projects in the
efferent or the afferent direction (Tuch et al., 2005; Owen et al.,
2007; Fonteijn et al., 2008). Moreover, DTI performs poorly in
regions where fibers merge or diverge (Mukherjee et al., 2008;
Peled et al., 2006; Ciccarelli et al., 2008), or when fibers turn
sharply (Wedeen et al., 2008). Finally, diseased or aged brains
often have altered DTI parameters that can affect the tractogra-
phy results (Clark et al., 2001; Beaulieu, 2002; Salat et al., 2005;
Camchong et al., 2009; Brubaker et al., 2009; Bava et al., 2009).
In animals, inwhich invasiveexperiments arepossible, analter-
native approach is to trace connections using MRI, following
injection of the contrast agent manganese chloride. This manga-
nese-enhancedMRI (MEMRI) tracing approach can reveal multi-
synaptic circuits, and it has found widespread use in a number of
animalmodels, including rodents, birds, and nonhuman primates
(Pautler et al., 1998; Saleem et al., 2002; Van der Linden et al.,
2002; Wu et al., 2006; Simmons et al., 2008; Chuang and Koret-
sky, 2009). However, the interpretation of manganese transport
and anatomy can be complicated because manganese is trans-
portedmultisynaptically. This uncertainty has beenpartially over-
come using precise timing to define the numbers of synaptic
steps along a given axonal pathway (Tucciarone et al., 2009;
Chuang and Koretsky, 2009). However, the uptake and transy-
naptic transport of manganese can reflect neuronal activity (Lin
and Koretsky, 1997; Aoki et al., 2002; Yu et al., 2005; Silva
et al., 2008; Eschenko et al., 2010a),which can further complicate
interpretations of the anatomical projections. Additional compli-
cations arise from a nonneuronal systemic diffusion of manga-
nese through the CSF or blood stream (Chuang and Koretsky,
2009). Also, manganese is toxic above a specific dose (Wu
et al., 2006; Simmons et al., 2008; Eschenko et al., 2010a,2010b).
Here, our goal was to develop and test a contrast agent
for MRI-based anatomical tracing that reveals monosynapticNeuron 70, 229–243, April 28, 2011 ª2011 Elsevier Inc. 229
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compound is a conventional tracer (cholera-toxin subunit-B;
CTB), made visible for MRI by conjugation with gadolinium-
chelates (GdDOTA, gadolinium-tetraazacyclododecanetetra-
acetic acid). Gadolinium-chelates are widely used as MRI
contrast agents in clinical studies (for reviews, see Graif and
Steiner, 1986; Sosnovik, 2008; Port et al., 2008). Combining
these two properties, we hypothesized that the CTB component
of the conjugate would be taken up by neurons and transported
axonally and that the GdDOTA component of the conjugate
would reveal the location of the transported compound based
on MRI.
We tested this compound in thewell-defined circuitry of the rat
brain. In the first experiment, GdDOTA-CTB was injected into
primary somatosensory cortex (S1) to test for local MR signal
enhancement in well-known thalamic targets of S1: the ventral
posterolateral thalamic nucleus (VPL), posterior thalamic nuclear
group (Po), and reticular thalamic nucleus (Rt) (Koralek et al.,
1988; Kaas and Ebner, 1998; Liu and Jones, 1999; Paxinos,
2004). MRI scans were performed at systematically varied time
points to measure the neuronal uptake and transport dynamics
of GdDOTA-CTB. In a second experiment, we validated the
above results by comparison with the immunohistochemical
staining of CTB in the same animals that previously received
GdDOTA-CTB injections and MRI. In addition, we evaluated
the extent of possible tissue disruption at the GdDOTA-CTB
injection sites using histology. Third, we demonstrated additional
MR enhancement in sites expected in/near the injection site,
including the gray matter, the underlying white matter and local
intrinsic connections. In addition, we also found patchy
enhancement in the caudate/putaman (CPu) in the regions
known to have connections with S1 (Gerfen, 1989; Kincaid and
Wilson, 1996; Hoover et al., 2003). The second and third exper-
iments also investigated the direction of transport and whether
or not the GdDOTA-CTB traces connections monosynaptically
versus multisynaptically. In a fourth experiment, we compared
the intraneuronal transport rate of GdDOTA-CTB with the extra-
cellular diffusion rate of GdDOTA alone, by injecting the two
compounds into comparable locations in S1. To confirm that
the tract-tracing properties of GdDOTA-CTB are mediated
by active uptake and axonal transport mechanisms, we also
performed control experiments using Gd-Albumin, a gadoli-
nium-conjugated serumprotein. This compound has amolecular
weight comparable to that of GdDOTA-CTB, but without any
known tract-tracing properties (Nagaraja et al., 2006; Astary
et al., 2010). Fifth, we compared the transport properties of
GdDOTA-CTB with those of the MEMRI, in an otherwise-
matched experiment. Finally, we investigated whether
GdDOTA-CTB can reveal neuronal tracts in other regions of
the brain, by testing it in the olfactory pathway of rats.
RESULTS
Thalamic Transport following S1 Injections
Following unilateral GdDOTA-CTB injections into S1, we found
target-specific enhancement in the main thalamic nuclei known
to be connected with S1, namely VPL, Po, and Rt (Figure 1).
This presumptive transport was observed when using multiple230 Neuron 70, 229–243, April 28, 2011 ª2011 Elsevier Inc.types of MR sequences: 2D and 3D T1-weighted (T1-W) and
3D T1- inversion recovery (T1-IR) (see Experimental Procedures
and Supplemental Information).
Depending on the MR sequence used, different brain regions
(e.g., white matter versus gray matter) were often enhanced
differentially in the raw MR images, because each type of brain
tissue has a different relaxation time. Figure 2 shows such image
variations across a rostrocaudal series through the thalamus
(Figures 2A and 2B), and the subtraction analysis (e.g., Fig-
ure 2C), which separated the experimentally induced MR
enhancements from this intrinsic background variation. Figures
2A–2C show results after extensive signal averaging. Figure 2A
was acquired during a 14 hr scan using the T1-IR sequence,
which yielded the highest image contrast; this was the single
ex vivo experiment that we performed. Images in Figures 2B
and 2C show the average from 9 scans over 3 scan sessions,
from a single in vivo case. At a threshold of p < 0.002 (uncor-
rected), the subtraction images (Figure 2C) confirmed enhanced
MR signals (presumptive transport) in thalamic targets VPL, Po,
and VM (i.e., the ventromedial thalamic nucleus), consistent with
known connections (Koralek et al., 1988; Kaas and Ebner, 1998;
Liu and Jones, 1999; Paxinos, 2004; MacLeod and James, 1984;
Desbois and Villanueva, 2001). Additional enhancement was
apparent in the raw images (e.g., Rt, in Figure 2B) but it did not
reach statistical significance at p < 0.002, given this level of
signal averaging. The lack of significance in Rt (Figure 2C) may
also reflect the small size of the nucleus, relative to the limits of
brain coregistration processes.
A second, simpler strategy for isolating enhancement was
to measure MR levels in mirror-symmetric locations in each
hemisphere from a common slice, then to use the contralateral
hemisphere as a control for that in the injected hemisphere.
For example, Figure 3 shows enhancements ipsilateral to the
S1 injection site in 4 slices centered on VPL, based on both
T1-W (Figures 3A and 3B) and T1-IR (Figures 3C and 3D)
sequences. In Figures 3A and 3B, the slice planes included
putative Rt. In the T1-W images, enhancement in VPL was typi-
cally 10%–20%. As expected, the background suppression
sequence (T1-IR) yielded higher contrast enhancement; in VPL,
this amounted to 70%–90%.
Our subsequent analyses focused on VPL, because VPL is the
largest of S1’s thalamic-recipient nuclei, and it includes somato-
topic map variations large enough to be resolved with MRI. Of
the 24 animals injected with GdDOTA-CTB into the forepaw
region of S1, all showedMR enhancements in the corresponding
forepaw representation of VPL.
Transport Dynamics
To resolve the time course of this presumptive transport, we
rescanned animals at a range of time points following the
GdDOTA-CTB injections: days 1–7, 1 week, 3 weeks, 4 weeks,
and 8 weeks. Figure 4 shows the level of MR enhancement
over time in VPL, in group-averaged data (n = 8). Themean signal
remained near baseline through day 2 postinjection. In this data
set, the signal increase became statistically significant on day 5
(p = 0.034), and reached a plateau near day 7, approximately
10% above baseline in these T1-W images. The enhancement
remained stable for at least 4 weeks postinjection and then
Figure 1. General Paradigm
(A) Typical example of an intra-cortical injection site. GdDOTA-CTB was injected into the forepaw representation of S1.
(B) Example of a brain section reacted for CO activity, showing the location and structure of somatosensory thalamic nuclei known to have direct connections with
S1. At this anterior-posterior level, these nuclei include the VPL, Rt, Po.
(C) MR images show clear and consistent enhancement in the presumed thalamic targets, ipsilateral to the injection site (red arrows). Examples are shown from
two different MRI sequences: T1-IR (left), and T1-W (right). MR images were acquired 7 days postinjection.
Related data are shown in Figures S1 and S2.
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peak MR enhancement (Figure 4) was consistent with the
survival times required for optimal CTB transport in conventional
histological studies (e.g., Ericson and Blomqvist, 1988; Bruce
and Grofova, 1992; Sakai et al., 1998; Angelucci et al., 1996).
Histological Confirmation of Transported GdDOTA-CTB
in Thalamic Target Zones
To verify the thalamic targets of the MR results, CTB immunohis-
tochemical staining was conducted in animals that had received
GdDOTA-CTB injections into S1 followed by MRI scans.
The connections of S1with VPL are known to be reciprocal: S1
projects to VPL, and S1 receives projections from VPL. In con-
trast, S1 connections with Rt are unidirectional: S1 projects to
Rt but does not receive projections from Rt (Kaas and Ebner,
1998; Liu and Jones, 1999; see also reviews Alitto and Usrey,
2003; Jones, 2007). If the GdDOTA-CTB were operating as
a classic neuronal tracer, injections of this compound into S1
should confirm these and related predictions based on known
anatomical features revealed by the CTB histology. For instance,
(1) CTB injections into S1 should label cell bodies and presyn-
aptic terminals in VPL, as localized by the MRI in the same
animals; (2) such CTB-labeled cell bodies should be absent in
thalamic regions immediately surrounding VPL, since thoseregions do not project to S1; (3) presynaptic terminals (from
S1) should be labeled byCTB in Rt; (4) all the CTB labeling should
be confined to the ipsilateral thalamus; and (5) CTB labeling
should be confined to the somatotopic subfield of VPL that
corresponds to the injected region in S1 (i.e., the forepaw repre-
sentation of VPL).
To test these predictions, brain slices from the thalamus and
S1 were stained using standard immunohistochemical proce-
dures (Bruce and Grofova, 1992; Angelucci et al., 1996; Sakai
et al., 1998, 2000; Wu and Kaas, 2000), from the same animals
in which MR images had been collected (see Figure 5). The
locations and boundaries of VPL and Rt were localized indepen-
dently, based on known cytoarchitectonic differences between
thalamic nuclei (for review, see Jones, 2007; Paxinos, 2004;
see also Figure 1B, CO-stained brain section).
All the above predictions were confirmed: (1) CTB-containing
cell bodies and terminals were found within VPL (Figures 5B–
5D); (2) such CTB-labeled cell bodies were absent in thalamic
regions surrounding VPL (see Figure 5D); (3) Rt showed the
typical ‘‘dusty’’ appearance of labeled presynaptic terminals
(Figure 5C), relative to the nonspecific background staining
(e.g., Bruce and Grofova, 1992; Sakai et al., 2000); (4) all labeling
was confined to the ipsilateral thalamus; and (5) the label in
VPL was confined to the somatotopically appropriate segmentNeuron 70, 229–243, April 28, 2011 ª2011 Elsevier Inc. 231
Figure 2. Continuity of Labeling across Thalamic Targets
Each panel shows the enhancement of MR signals in presumptive VPL and Po across a series of slices 100 mm thick, spaced 200 mm apart. Rt and VM are
included at the margins of this slice series.
(A) The average of 26 T1-IR scans, acquired during one scan session, from a single ex vivo case.
(B) An average of 9 T1-W scans in vivo, across 3 scan sessions.
(C) The same slices as in (B), after normalization, coregistration, and subtraction of baseline images. Voxels showing significant enhancement (p < 0.002,
uncorrected) are shown in red. Intrinsic midline enhancement is the fornix, a white matter tract.
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MRI Tracer Reveals Neural Connections In Vivo(i.e., the crescent moon-shaped subfield of VPL, in Figures 5A
and 5B), consistent with the highly topographic patterns of
anatomical connections known from previous studies (Fabri
and Burton, 1991a; Hoover et al., 2003; see Jones, 2007 for
review).
Histological Evaluation of Tissue Disruption
after GdDOTA-CTB Injections
Although CTB was not toxic in previous studies (see Ishitsuka
and Kobayashi, 2008), it could be argued that transport proper-
ties of the GdDOTA-CTB were complicated by increased osmo-
larity or chemical toxicity, at much higher concentration at the
injection site. To test this, we did a control experiment of injecting
comparable volumes (1 ml) of saline or GdDOTA-CTB (50%) into
S1 in 4 additional animals, followed by sacrifice 5 days postinjec-
tion. Subsequent histology of the injection sites revealed that232 Neuron 70, 229–243, April 28, 2011 ª2011 Elsevier Inc.GdDOTA-CTB injections produced tissue disruption compa-
rable to that in the saline control (see Figure S1 available online).
Thus, the GdDOTA-CTB was not obviously toxic at the injection
sites, at the present concentration.
Connections with the Caudate/Putaman
The S1 injections also produced MR enhancement in the most
dorsolateral region of the caudate/putamen (CPu) (Figure S2).
This region is known to receive direct inputs from the forepaw
representation of S1 (Hoover et al., 2003) and to show forepaw
responses physiologically (West et al., 1990; Brown, 1992;
Brown and Sharp, 1995). The MR enhancement was discontin-
uous and restricted to patches, approximately 200–400 mm in
diameter. The size and location of these patches suggests that
the GdDOTA-CTB projects into striasomes, as reported based
on conventional tracers and immunocytochemical staining
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Figure 3. Spatial Profile of MR Enhancement in Thalamic Target Zones
Images were acquired 7–30 days following GdDOTA-CTB injections into right S1, in three animals. In all cases, clear enhancements were found in VPL (white
arrows); in some cases the slice plane also included Rt. In each panel, the slice of interest is shown at the top, and the bottom shows the corresponding
measurements from mirror-reflected lines passing through the ipsilateral (red) versus contralateral (green) thalamus.
(A and B) Data acquired using T1-W sequences.
(C and D) Data acquired using T1-IR sequences. In all cases, MR image intensity was enhanced in ipsilateral VPL compared to contralateral VPL. In each section,
the MR signal intensity was sampled along a line (300 mm width) extending from the midline of the brain toward the internal capsule, in both directions.
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AB
Figure 4. Transport Dynamics
(A) Following GdDOTA-CTB injections into S1, the
enhancement in VPL remained stable from 7 days
through at least 1 month after injection. T1-IR
images are illustrated.
(B) Detailed time course of MR signal changes in
VPL, averaged from T1-W images (n = 8). Most of
the enhancement occurred between 5 and 7 days
following injection. The enhancement remained in
the thalamus for up to 1 month, and cleared by
2 months postinjection.
Group data are presented as a mean ± SEM.
Related data are shown in Figures S4 and S5.
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MRI Tracer Reveals Neural Connections In Vivo(Graybiel and Moratalla, 1989; Gerfen, 1989; Schoen and
Graybiel, 1993; Kincaid and Wilson, 1996; Hoover et al., 2003).
Tracing White Matter Fiber Bundles with GdDOTA-CTB
As early as 4–5 days after GdDOTA-CTB injections, enhance-
ment could be clearly detected in the white matter just beneath
the injection sites. Such enhancement could be traced along
the rostrocaudal direction in the horizontal plane (Figure S3A),
and along themediolateral direction in the coronal plane (Figures
S3B–S3G). Note that white matter enhancement only appeared
after a few days postinjection. Thus, presumably the enhance-
ments resulted from active transport in the white matter tract,
rather than from contamination of the white matter at the time
of injection. Immunohistochemical staining confirmed the pres-
ence of CTB-labeled axons in the corresponding location of
the white matter (Figure S3C compared to Figure S3D). The
MR enhancement could be seen both in the raw images (Fig-
ure S3F) and in the quantitative subtraction (Figure S3G) from
the same animal.
Labeling of Intrinsic Cortical Connections
In some cases, we found that cortical injections of GdDOTA-CTB
produced a band of horizontally oriented, elongated enhance-
ment in the middle layer(s) of cortex, running parallel to the brain
surface (arrows in Figures 6A–6C). This result was especially234 Neuron 70, 229–243, April 28, 2011 ª2011 Elsevier Inc.prominent when the injection core
involved the superficial cortical layers.
This evidence suggests intrinsic transport
of the GdDOTA-CTB, a common finding
in studies using classic neural tracers.
To test this interpretation, Figure 6
shows the CTB immunohistochemical
staining at higher magnification (Figures
6D–6F). Clearly, CTB-labeled pyramidal
neurons were found in layers II, III, and
V, with axonal processes and extensive
apical dendrites. It is well known that the
apical dendrites from the cortical pyra-
midal cells extend to (plexiform) layer I
(for review, see Cauller, 1995; Rubio-Gar-
rido et al., 2009; see also Figure 2 inWang
et al., 2009). Thus, our results suggest
that the bands of MR enhancement withinS1 reflect (at least in part) the labeled pyramidal neurons in layers
II, III, and V, with their apical dendrites extending to the superfi-
cial cortical layers.
Labeling of Cortico-cortical Connections
Injections into the forepaw representation of S1 also enhanced
MR signal in the adjacent M1 cortex (Figure 6C). Based on the
location previously reported from microstimulation mapping
experiments and the standard brain atlas, the enhancement
we observed was restricted to the forepaw representation of
M1 (Donoghue and Wise, 1982; Neafsey et al., 1986; Paxinos
and Watson, 2004). This is consistent with the extensive and
topographically organized intercortical connections between
S1 and M1 described in earlier studies (Akers and Killackey,
1978; Donoghue and Parham, 1983; Fabri and Burton, 1991b;
Colechio and Alloway, 2009; Izraeli and Porter, 1995). The M1
enhancements took the form of a thick band-like pattern
concentrated in the middle part of the cortex. Judging from its
laminar location and thickness, and our CTB histology, this
band-like enhancement appears to include layers III through V.
In many cortical systems, one would expect to find callosal
connections to corresponding cortical areas in the contralateral
hemisphere. For instance, such ‘‘homotypical’’ callosal connec-
tions have been demonstrated between S1 representations of
the jaw, whisker barrels, and midline body. However, evidence
Figure 5. Histology of GdDOTA-CTB
Following S1 injections, putative GdDOTA-CTB transport into the thalamic
nuclei was verified with histological staining for CTB.
(A) MSME (T1-W) images show the distinctive semicircular-shaped enhance-
ment in the forepaw representation of VPL.
(B) In the corresponding location, a histological section verified the transport
zones by CTB staining. The location of MR enhancement (from A) is outlined
with reddish-brown dashed lines, and the border of VPL is outlined with shorter
black dashed lines. The labeled terminals are shown at higher magnification in
the inset to the right (C).
(D) CTB-labeled cell bodies and sparse presynaptic terminals in VPL (left), and
labeled presynaptic terminals in Rt (right). In other sections, labeled terminals
were also found in VPL, but cell bodies were not labeled anywhere in Rt. As
described in the literature, we found that presynaptic labeling in VPL was
regionally variable. Here, the cell bodies were more prominently labeled,
although presynaptic terminals are also evident. MR images were taken
7–10 days postinjection, and histological processing was done immediately
thereafter. Scale bar = 0.1 mm. Overall, the GdDOTA-CTB confirms previous
tracer studies of CTB, showing that the projections of S1 terminate in VPL, with
collaterals terminating in Rt.
Neuron
MRI Tracer Reveals Neural Connections In Vivofrom classical tracers (Akers and Killackey, 1978; Killackey and
Fleming, 1985; Iwamura, 2000; Hayama and Ogawa, 1997; Man-
zoni et al., 1989) has shown that such callosal connections are
extremely weak or absent between S1 forepaw representation
(i.e., the site injected here). Therefore, our finding a lack of cal-
losal enhancement is consistent with previous negative results.Time Course of Uptake and Decay at the S1
Injection Site
Figure S4 shows the time course of the MR enhancements at
the injection site throughout the week following S1 injections.
Prominent signal increases were observed immediately (1–2 hr)
after the injections of GdDOTA-CTB. In the injection site cores,
the enhancement was relatively weaker, presumably reflecting
the known shortening of T2 signals at high gadolinium concen-
trations (Figure S4A; 1–2 hr). After day 3, the enhancement in
the injection cores contracted slightly, and the borders were
sharpened—but otherwise the size and shape of the injection
site remained stable for a month thereafter (Figures 7A and 7D,
day 5 and week 3; Figure S4A, days 5 and 7; Figures S6A
and S6C, 90 hr and 170 hr). Group statistical measurements
(n = 11) confirmed that the level of signal enhancement in the
injection sites also reached asymptote on day 3, and remained
relatively stable for a month after the injection. Enhancement at
the injection site was largely cleared by 2 months postinjection
(Figure S4C, red line), similar to the time course of the trans-
ported compound in VPL (Figure 4B).
Thus, in both the injection site and the transport targets, the
time course of GdDOTA-CTB enhancement was fully consistent
with neuronal uptake of the tracer CTB; presumably extracellular
diffusion of GdDOTA alone would clear much faster. To confirm
the latter, we directly measured the rate of extracellular diffusion
by injecting GdDOTA alone into S1 (n = 4). GdDOTA injections
immediately produced a strong signal enhancement throughout
a large region of the cortex, as one would expect from rapid
extracellular diffusion (Figure S4B, blue line in S4C). Moreover,
the enhancement due to GdDOTA alone cleared extremely
rapidly: it peaked at the first data point, immediately after injec-
tion, and it cleared completely within 24 hr. Thus, the GdDOTA
was completely cleared well before the enhancement due to
neuronal transport (i.e., from the GdDOTA-CTB) peaked (days
5–7, cf. red versus blue lines in Figure S4C).
An additional control experiment was designed to further
rule out the possibility that GdDOTA-CTB transport can be
mediated by nonselective, passive uptake and diffusion. To
test that hypothesis, we injected another contrast compound,
Gd-Albumin, in which the gadolinium was conjugated with
bovine serum albumin (a protein that has a molecular weight
similar to CTB). Although the injected gadolinium concentration
from Gd-Albumin was comparable to the GdDOTA-CTB (i.e.,
65–75 mM), and the protein concentration from Gd-Albumin
was also very high (30% protein), we found that the signal
intensity at the Gd-Albumin injection sites was much weaker
(compare Figure S4, red line, and Figure S5, solid black line),
and the enhancement was much smaller, indicating that
Gd-Albumin was rapidly cleared immediately after injection.
The signal intensity at the injection core continued to decrease
on day 4, returning to baseline values by day 7 (Figure S5).
Except for the focal injection cores, no enhancement was
present anywhere in the brain, including the thalamus, at any
MR imaging time point.
Overall, these data further support the conclusion that the
GdDOTA-CTB conjugate is actively and selectively taken up
and transported within the brain, as a MR-visible anatomical
tracer.Neuron 70, 229–243, April 28, 2011 ª2011 Elsevier Inc. 235
Figure 6. GdDOTA-CTB Labeling of Intrin-
sic Cortical Connections
Following cortical injection of GdDOTA-CTB into
S1, T1-W (A–C) images revealed bands of MR
enhancement in the middle layer(s) of cortex
(arrows), parallel to the cortical surface. These
enhanced bands were especially apparent when
the injections involved the superficial cortical
layers (e.g., A–C).
(C) Statistical data confirmed this observation
from the corresponding slice at the same magni-
fication in different animals, indicating extrinsic
connections linking areas S1 and M1, as well as
intrinsic connections linking different body repre-
sentations within S1 (red arrows in A and B; black
arrows in C). Statistic p value < 0.05, uncorrected.
(D–F) At higher magnification, CTB-labeled pyra-
midal neurons were found in layers III and V, with
clear axonal processes and apical dendrites. This
suggests that the enhancements in layers III and V
arise from the apical dendrites of the pyramidal
neurons in those layers, which extend into the
superficial cortical layers.
Scale bars in (A)–(C), 1 mm; in (D)–(F), 0.1 mm.
Related data are shown in Figure S3.
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To clarify the relative advantages or disadvantages of GdDOTA-
CTB, we compared GdDOTA-CTB results with comparable data
using the tract-tracing contrast agent manganese. For both
tracers, the signal intensity was measured at both the S1 injec-
tion site and the thalamic transport site, at comparable time
points across tracers (i.e., immediately postinjection, at and after
peak transport times for the two tracers). The two contrast
agents were injected at the same concentration and volume.
In the S1 injection site, these experiments confirmed that the
GdDOTA-CTB was strikingly punctate and spatially stable
throughout the following weeks in each of the major cortical
layers (Figures S6A and S6C). By contrast, comparable injec-
tions of manganese spread widely and quickly (Figures S6B
and S6D).
The increased spatial specificity of the GdDOTA-CTB injec-
tions was evident in both horizontal (i.e., along the dorsolateral
surface of the cortex) and vertical (i.e., across cortical layers)
directions. As shown in Figures S6A and S6C, the pattern of
signal enhancement at 50 hr after injection was near-identical
to that measured 170 hr after injection, with a half-amplitude at
half-maximum (HAHM) of 1–1.8 mm, measured away from the
midline, in all layers. This remarkable spatial specificity was
found in all animals studied (Figure 7A, left panels, and 7D, top
middle panel). As expected, the center of the injection core
was not enhanced, reflecting signal dropout due to the T2 short-
ening effect at high concentrations of the contrast agent.236 Neuron 70, 229–243, April 28, 2011 ª2011 Elsevier Inc.In comparison, enhancement due to
manganese at the injection sites spread
rapidly, in both axes. As early as 1–2 hr
after injection (i.e., the earliest possible
data acquisition point), manganese en-
hancement at the injection site (involvingthe supragranular layers) was quite extensive (HAHM = 4–
6 mm) in the horizontal direction within the supragranular
layers, nearly triple that of the GdDOTA-CTB extent (Figure S6,
top panels of B and D, and Figure 7B, top left panel). By 10 hr
postinjection, the MR enhancement spanned all cortical layers
in the vertical dimension, and also increased in the horizontal
dimension (Figure S6, lower panels of B and D). Existing
evidence suggests that these rapid changes in manganese
enhancement at the injection site reflect a combination of
diffusion and continued uptake. The diffusion may be medi-
ated via the CSF, at least in part (Liu et al., 2004; Chuang
and Koretsky, 2009), due to the small molecular weight of
the manganese. Therefore, the growing size of the injection
site likely reflects manganese transport by the neurons at the
site of diffusion, followed by further diffusion, uptake, and
transport, and so on.
Similar differences were also observed in the thalamic trans-
port sites, in comparisons between these two tracers. After a
relatively short period of time, manganese enhancement
appeared in multiple subfields and nuclei, including some that
are not confirmed by classical neuroanatomical tracer data. As
early as 12 hr following manganese injection into S1, regions
such as the subthalamic nuclei and sustantia nigra are promi-
nently enhanced (data not shown, but see Tucciarone et al.,
2009, Figure 2A)—even though these regions do not have direct
connections with S1 (Fujimoto and Kita, 1993; see also Paxinos,
2004 for review).
Figure 7. Spatial and Temporal Variations
in Thalamic Transport Targets
This figure shows the thalamic transport zones at
different time points in the same animals. As
controls, results are also shown from the injection
sites, from the same cases.
(A) The thalamic transport zones following
GdDOTA-CTB injections are patchy; transport is
confined within subfields of the thalamic nuclei
that have known somatotopic connectionswith S1
(C and D). These results are consistent and very
stable for several weeks, until the transported
compound clears.
(B) After manganese injections, the thalamic
transport zones expand within a few hours. The
expansion extends through the different subfields
of thalamic nuclei and to other neighboring
nuclei that do not have known connections with S1
(C and D).
Related results are shown in Figure S6.
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zones, the enhancements remain at the same location and at
a constant size (Figure 7A, right panels, Figure 7C, middle panel,
and Figure 7D, lower middle panel). In addition, the pattern of
GdDOTA-CTB enhancement in the transport zones is patchy,
consistent with the pattern obtained from conventional tracers,
which indicate that only specific subfields of the nucleus are
connected with the injection site (Figure 7C, middle panel). By
contrast, manganese enhancement at the transport zones,
within a few hours after injection, rapidly spread into neighboring
regions, including different subfields of the same nucleus, and
even into different nuclei (Figure 7B, right panels, Figure 7C,
lower panel, and Figure 7D, lower right panel).
Thus, compared with the GdDOTA-CTB, it is more difficult
to use manganese to reveal the precise zones that are directly
connected with the injection site, if transport results are not
timed precisely. This can be especially challenging if transport
is faster for some targets (e.g., closer targets) compared toNeuron 70, 229–2others (further away from the injection
site). In such cases, perhaps no single
transport time is optimal.
Injections in the Olfactory Pathway
To test for transport in a peripheral neural
pathway, we injected GdDOTA-CTB
unilaterally into the nostril cavity (n = 2).
Strong signal enhancement was ob-
served in the olfactory epithelium, exclu-
sively ipsilateral to the injection, as early
as 12 hr following the injection (i.e., the
second MRI time point). By day 2, robust
enhancement was clearly detected
throughout the olfactory epithelium and
along the olfactory tract ipsilateral to the
injection (Figure 8A). Weaker enhance-
ment was also found in the outer layer
of the inferior olfactory bulb (OB, i.e., theglomeruli layer). Some individual glomeruli in the specific region
of the OB could be easily identified based on the MRI enhance-
ment patterns (Figure 8B). Enhancement in these regions lasted
up to 7 days. The injection of GdDOTA-CTB into one nostril did
not enhance signal in the contralateral nostril pathway, consis-
tent with the known anatomical evidence (for review, see Imai
and Sakano, 2008; also see Kikuta et al., 2008, Figure 1).
Together, these results suggest that GdDOTA-CTB can be
used to trace peripheral anatomical pathways, in addition to
central ones.
Following unilateral injection of the OB, MR signal enhance-
ment was found on day 7 in other regions of the OB, and in
part of the ipsilateral anterior olfactory nucleus (AON; Figure 8C).
Weaker enhancement could also be detected in the ipsilateral
projection of the central olfactory pathway to pyriform cortex
(Figure 8C). The location and pattern of GdDOTA-CTB transport
is consistent with known olfactory pathways using conventional
tracers (Smithson et al., 1989).43, April 28, 2011 ª2011 Elsevier Inc. 237
Figure 8. GdDOTA-CTB Transport in the Olfactory Pathway
(A) T1-W images in the sagittal plane, acquired two days after unilateral nostril
injections. GdDOTA-CTB strongly enhanced the entire peripheral olfactory
projection to its central target OB. Prominent signal increases were also
detected in the olfactory epithelium (red arrowheads), the olfactory nerve tract
(ON, long red arrows). Note that injection of GdDOTA-CTB in one nostril did not
enhance signal in the contralateral nostril pathway.
(B) T1-W images in the coronal plane at a different level (a and b, as shown in
the box), acquired 7 days after a right nostril injection. In addition to the
olfactory epithelium (red arrowheads) and olfactory nerve tract (red arrows), in
the outer glomeruli layer of the OB, some individual glomeruli were also
enhanced (blue arrowheads).
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To our knowledge, this study is the first to demonstrate brain
connections in vivo, using a purpose-designed compound
combining a classic neuroanatomical tracer (here, cholera-toxin
subunit-B, CTB) with a known MRI-visible label (gadolinium-
chelate, GdDOTA). When injected into S1 of rats, this compound
produced a distinct enhancement of MR signal in multiple known
thalamic targets of S1, including VPL, Rt, Po, and VM, in the
hemisphere ipsilateral to the injection site (see Figures 1C
and 2). Moreover, the presumptive transport was somatotopi-
cally specific: injections aimed in the forepaw representation of
S1 produced MR enhancement in the middle subfield of VPL,
which corresponds to the forepaw representation in that
thalamic nucleus (see Figures 1C, 2, 3, 5A and 5B, and 7C,
middle panel).
This MR evidence for neural transport was confirmed by
histology. Histological staining showed definitive CTB transport
in the same thalamic nuclei that showed enhancement in the
MR images, within the same animals, in the expected cellular
compartments. For example, cell bodies and terminals were
labeled in VPL, whereas only terminals were labeled in Rt
(Figures 5B–5D).
Outside the thalamus, the GdDOTA-CTB also showed addi-
tional MRI properties consistent with those known from classic
tracers. This evidence included stable and long-lasting enhance-
ment of MRI at the injection site, laminar-specific intrinsic
connections near the injection site, connections with ipsilateral
striatum and M1, and white matter projections beneath the
injection site.
Time Course of Transport
Crucially, the time course of the thalamic MR enhancement is
consistent with the interpretation of axonal transport of the
GdDOTA-CTB compound. That MR enhancement began in the
thalamic targets only after 2–3 days, and the enhancement
peaked from 1–4 weeks postinjection (see Figure 4B).
To the extent that it is known, histological evidence on CTB
transport matches the time course of the presumptive transport
of GdDOTA-CTB into thalamus, based on MRI. For axonal
distances comparable to those in this study, CTB transport
can first be detected 3–4 days following injection, and
7–14 days yield optimal results (Bruce and Grofova, 1992; Eric-
son and Blomqvist, 1988; Angelucci et al., 1996; Sakai et al.,
1998). This similarity in time courses strongly supports our
hypothesis that the MR signal enhancement in thalamus reflects
active neuronal transport of GdDOTA-CTB to/from S1.
By comparison, MR enhancement due to passive extracellular
diffusion (from GdDOTA injections into S1) peaked and then
cleared within a day (see Figures S4B and S4C)—i.e., 4 days
before the thalamic MR enhancement due to presumptive trans-
port fromGdDOTA-CTB reached statistical threshold.Moreover,
the extracellular diffusion (GdDOTA alone) spread quite widely,(C) Signal enhancement in the central olfactory pathway 7 days following OB
injection. MR levels were enhanced in the anterior olfactory nucleus (AON) and
pyriform cortex (PCX).
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injections. Thus, the GdDOTA-CTB results were quite distinct
from those due to extracellular diffusion, both temporally and
spatially.
Although the GdDOTA-CTB showed strong and stable MR
enhancement for long periods of time (at both the injection site
and the targets), injections at similar concentrations of the
control contrast compound, Gd-Albumin, cleared rapidly at the
injection site—despite having a similar molecular weight. This
suggests that local astrocytes and neurons take up Gd-Albumin
nonspecifically. Moreover, the lack of transport of the Gd-
Albumin here and previously (Nagaraja et al., 2006; Astary
et al., 2010) indicates that the GdDOTA-CTB works successfully
as a unique MRI-visible tract-tracer, based on active uptake and
transport processes.
Optimizing MRI Enhancement
Using conventional T1-W MR sequences, GdDOTA-CTB
produced a thalamic enhancement of 10%–20% above the
background MR level. A more targeted background-suppres-
sion T1-IR MR sequence yielded much higher signal increases
(80%). However the exact level of statistical sensitivity of this
technique will vary widely depending on multiple technical
factors. For instance, increases in the number of scans will
increase the SNR ratio, in accord with the well-known inverse
square law of signal averaging (I = 1/d2). Difference imaging
(e.g., Figure 2C) will also increase the statistical sensitivity.
Difference imaging has been crucial in the fields of fMRI and
optical recording, which are routinely based on significant signal
variations as low as 0.1%. Thus, the current GdDOTA-CTB
procedure produces signal changes that are well above the limits
of statistical uncertainty.
Another crucial factor is the tracer molecule itself. For
instance, the optimal ratio of Gd to CTB is not known. Results
here were achieved with a ratio of 1.3–3 Gd/protein. However
in a separate batch with up to 5 Gd per CTB (not described
here), transport was not detected. Thus there may be an upper
limit to the number of Gd that can be chelated and still yield
effective CTB transport. Presumably, ratios that are too low
sacrifice MRI sensitivity, whereas ratios that are too high may
compromise uptake and/or transport.
The level of MR enhancement will also vary with the density of
Gd reaching the target, which in turn reflects the divergence or
convergence of those neural connections. Here, our injections
were concentrated in 3-4 mm3 of S1 cortex. S1 projections
converge onto, and arise from, much smaller (1 mm3) thalamic
targets in VPL and Po; other thalamic targets are even smaller.
Thus the convergence of these connections may concentrate
Gd levels in thalamus. Anatomical studies support this idea: it
has been reported that connections to/from S1 are more abun-
dant with the thalamus (up to 1:40), compared with cortical
targets (Sherman and Koch, 1990). This factor may partially
explain why cortico-cortical connections (e.g., from S1 to ipsilat-
eral S2) were not apparent in our experiments, because cortical-
cortical connections do not show such convergence. Technical
limitations due to coil size and placement also reduced the
detection of MR enhancement in S2 (see Supplemental
Information).Toxicity and Tissue Damage after Intracortical
Injections
Inevitably, insertion of an injection needle into the brain produces
tissue damage along the needle track at the site of injection; it
can also cause a small necrotic zone at the center of the needle
tip (Figure S1). The relationship between transport and such
tissue damage has a long and complex history in the literature
on classical tracers. For example, it has been reported that
injections of CTB in large volumes, or rapidly by pressure, can
produce damage at the injection site (Conte et al., 2009a,
2009b). However, such tissue disruption is comparable following
injections of the same amount of saline. Therefore, the important
issue is whether damage occurs in the transport zones. Based
on saline injection controls (Figure S1) and histology, we found
no evidence of damaged cells in the transport zones. Even after
long survival times postinjection, we did not observe decays in
MR enhancement, thus ruling out the possibility of secondary
degeneration in these remote transport zones.
Anterograde versus Retrograde Transport
Histological studies have shown that CTB is transported in both
directions along axons, both retrogradely to cell bodies and
anterogradely to presynaptic terminals (Luppi et al., 1986; Bruce
and Grofova, 1992; Angelucci et al., 1996; Sakai et al., 1998,
2000; Wu and Kaas, 2000). Is our CTB-based compound also
transported in both directions? The current results clarify half
of this two-part question. As is typical in the brain, transport
from S1 to VPL, and from S1 and Po, are known to be reciprocal.
Thus in these areas, our MR enhancement does not distinguish
between the two directions of transport. However, connections
between S1 and Rt and CPu are atypically unidirectional: S1
projects to both Rt and CPu, but neither Rt nor CPu projects
back to S1 (Kaas and Ebner, 1998; Liu and Jones, 1999. Gerfen,
1989; Kincaid andWilson, 1996; Hoover et al., 2003). In addition,
it is known that sensory neurons in the olfactory epithelium
project anterogradely to the OB. Thus we can conclude that
the GdDOTA-CTB is transported anterogradely, at least.
Other Techniques of Tracing Connections: Manganese
Injections of manganese chloride, coupled with MR imaging
(MEMRI), have also been widely used to map brain connections
in vivo (Pautler et al., 1998; Saleem et al., 2002; Wu et al., 2006;
Tucciarone et al., 2009; Chuang and Koretsky, 2009). However, it
is complicated to interpret the relationship of MEMRI data to the
density of anatomical connections. First, MRI enhancement due
to manganese reflects functional (i.e., calcium-related) activity
(Lin and Koretsky, 1997; Aoki et al., 2002, 2004; Yu et al.,
2005; Eschenko et al., 2010a) as well as anatomical connections.
Second, manganese may be released from tissue after uptake
(unpublished observations); manganese at the injection sites
spreads quickly and continuously (e.g., Figures 7 and S6, see
also Tucciarone et al., 2009). Thus MEMRI has not been used
to measure connections across very small distances, such as
those across cortical laminae. Third, manganese is transported
multisynaptically, not monosynaptically. In some experiments,
this multisynaptic transport can be an advantage. However as
described above, this can be a disadvantage if it is crucial to
define each serial step of a given circuit. Moreover, diffusion ofNeuron 70, 229–243, April 28, 2011 ª2011 Elsevier Inc. 239
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produce nonspecific transport.
For these reasons, it can be challenging to distinguish which
factor produces the observed MR enhancement in MEMRI
studies. Additional measurements may be necessary. For
instance, results from MEMRI have been compared to those
from a classical tracer, to distinguish activity-dependent trans-
port of manganese from anatomically based transport (Wu
et al., 2006; Saleem et al., 2002).
The GdDOTA-CTB technique does not have these problems.
Moreover, apparent disadvantages of the GdDOTA-CTB may
be resolved by slight changes in procedure. For instance, multi-
synaptic connections could still be resolved using the monosyn-
aptic transport of GdDOTA-CTB, using serial injections. For
example, injections of GdDOTA-CTB into site A would produce
transport to site B. Then a later MR-targeted injection into site
B would produce transport to site C, and so on.
Other Techniques of Tracing Connections: Iron Oxide
Previous studies (Enochs et al., 1993; van Everdingen et al.,
1994) reported slow transport (5 mm/day) of dextran-coated
iron oxide compounds, which were visible using MRI. However,
that compound was specifically not transported in the central
nervous system (CNS), when injected into either the superior
colliculus or the eye (Enochs et al., 1993). Prior to our use of
GdDOTA-CTB, we also tested for CNS transport using an
iron-labeled compound (biocytin conjugated with iron oxide).
Consistent with the above findings, we also found that the biocy-
tin-iron oxide compound did not produce transport, perhaps
because iron-based compounds are too heavy to be transported
easily in the CNS.
Other Techniques of Tracing Connections: Classical
Tracers
The in vivo MRI-based tracer approach reveals connections that
would be difficult or impossible to study otherwise. However,
current MRI tracers will not supplant classical tracers (e.g.,
HRP, CTB, WGAHRP, etc.) because the latter can distinguish
labeled cells from labeled presynaptic terminals, and thus reveal
retro- versus anterograde transport. Accordingly, classical
tracers remain the gold standard, when such tracers are
compatible with the experimental goals.
Other Techniques of Tracing Connections:
DTI and Functional Connections
Based on MRI, connections between specific brain areas have
been inferred based on DTI (Le Bihan et al., 2001; Beaulieu,
2002; Tuch et al., 2005) and correlated resting state activity in
fMRI (Shmuel and Leopold, 2008; Margulies et al., 2009; Teipel
et al., 2010). However, neither of those noninvasive techniques
can definitively show whether or not cells in a given brain region
send or receive axons from another specific brain region.
Recently, invasive studies in animals have demonstrated
functional connections more directly, by combining fMRI with
electrical microstimulation of a targeted neural site (Tolias
et al., 2005; Ekstrom et al., 2008, 2009; Moeller et al., 2008; Field
et al., 2008). Although this technique raises exciting new possi-
bilities, it has its own limitations. Anatomical connections can240 Neuron 70, 229–243, April 28, 2011 ª2011 Elsevier Inc.only be inferred, because the white matter pathways are not
revealed. Moreover, the technique does not distinguish mono-
synaptic connections from multisynaptic ones. By comparison,
the interpretation of anatomical connections using GdDOTA-
CTB is simpler; it has all the properties of a classic neural tracer,
without requiring animal sacrifice.
Future Applications
Presumably, future applications of the GdDOTA-CTB approach
(perhaps in combination with other MRI-based techniques,
such as DTI, resting state fMRI, and/or MEMRI) will furnish a
much richer in vivo diagram of brain circuitry. At a practical
level, this MR-visible tracer can be used to target anatomically
connected regions, using electrophysiological microelectrodes
and/or serial tracer injections. More generally, this in vivo
approach can reveal changes occurring during plasticity induced
bynormal or abnormal physiology (e.g., axonal pruningor sprout-
ing), in both central and peripheral nervous systems (Rakic et al.,
1986; LaMantia and Rakic, 1990; Wu and Kaas, 2000, 2002; Raff
et al., 2002; Medana and Esiri, 2003; Prince et al., 2009).
EXPERIMENTAL PROCEDURES
GdDOTA-CTB Synthesis and Gd-Albumin Preparation
GdDOTA-CTB was made in-house using commercially available products.
The detailed synthesis procedures are described in the Supplemental Informa-
tion. Gd-Albumin was purchased commercially (Biopal Inc, Worcester, MA;
cat# P-00P01-100) and was lyophilized and rediluted in double distilled water
to a final concentration of 30% in protein and 65 mM in Gd solution.
Animals, Surgery, and Injections
Forty-one adult Sprague-Dawley rats (280–350 g) were used in these experi-
ments (29 injected with GdDOTA-CTB, 4 GdDOTA injections, 3 Gd-Albumin
injections, 1 saline injection, and 4 MnCl2 injections). In experiments #1–3,
a total of 24 rats received unilateral intracortical injections of GdDOTA-CTB
into area S1, and 1 received saline injection into area S1. In experiment #4, 4
rats received injections of GdDOTA in area S1 and 3 received injections of
Gd-Albumin in S1. In experiment #5, we compared injections of manganese
chloride (MnCl2; n = 4) with GdDOTA-CTB to measure diffusion and transport
dynamics in both the S1 injection site and the thalamic transport zones. In
experiment #6, 4 additional rats received a unilateral injection of GdDOTA-
CTB in the nostril cavity (n = 2) or the OB (n = 2). One additional rat was
scanned for 14 hr ex vivo, 7 days after an S1 injection of GdDOTA-CTB. All
experiments were performed in compliance with guidelines set by the ACUC
of the NINDS, NIH. Surgical details and procedures regarding the injections
are given in Supplemental Information.
MRI Data Acquisition
GdDOTA-CTB Injections
Animals were imaged prior to injection (‘‘baseline’’), and immediately (1–2 hr)
after injection, on days 1–7 postinjection, and at longer intervals for up to
2months postinjection. Four animals were imaged for 7–10 days postinjection,
then sacrificed for histology.
GdDOTA Injections
GdDOTA alone was injected into the S1 forepaw, using the same coordinates
as in the GdDOTA-CTB experiments. MRI data were acquired at the baseline,
immediately after injection, and every 12 hr until day 2. The last image was
acquired on day 5 postinjection.
Gd-Albumin Injections
Animals received unilateral injection of Gd-Albumin into the S1 forepaw.
Animals were imaged immediately after injection and imaged on days 4 and
7 after injection. MRI data were acquired at the injection sites and throughout
the brains.
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MnCl2 was injected into S1 forepaw, using the same procedures described
above. MRI data were acquired every 2 hr until 10 hr postinjection.
2D and 3D spin-echo multislice multiecho (MSME) and rapid acquisition
with relaxation enhancement (RARE) images pulse sequences were used to
acquire T1-W MR images. The 3D modified driven equilibrium Fourier trans-
form (MDEFT) pulse sequence was used to acquire T1-IR images. Additional
details regarding 11.7T and 7T MRI data acquisition parameters and proce-
dures are described in the Supplemental Information.
MRI Data Analyses
To measure the enhancement in the thalamic target zones due to GdDOTA-
CTB transport, we used both region of interest (ROI) and 3D image volume
substraction analyses. To measure the speed of signal decay at the injection
site, we used ROI analyses. The details of these two analysis techniques are
given in the Supplemental Information.
Perfusion, Histology, and Photoimaging
Details concerning animal perfusion, histology, and photoimaging are
described in the Supplemental Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and Supplemental Experimental
Procedures and can be found with this article online at doi:10.1016/j.neuron.
2011.03.010.
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